Business Description
Vivoryon Therapeutics NV
ISIN : NL00150002Q7
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 752.18 | |||||
Equity-to-Asset | 0.85 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.1 | |||||
3-Year EPS without NRI Growth Rate | -10.5 | |||||
3-Year FCF Growth Rate | -6 | |||||
3-Year Book Growth Rate | -8.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.22 | |||||
9-Day RSI | 48.2 | |||||
14-Day RSI | 49.46 | |||||
6-1 Month Momentum % | -70.58 | |||||
12-1 Month Momentum % | -80.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.37 | |||||
Quick Ratio | 9.37 | |||||
Cash Ratio | 8.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.3 | |||||
Shareholder Yield % | -54.44 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 85.5 | |||||
Operating Margin % | 795.44 | |||||
Net Margin % | 782.93 | |||||
FCF Margin % | 609.25 | |||||
ROE % | -90.14 | |||||
ROA % | -79.05 | |||||
ROIC % | -1722.16 | |||||
ROC (Joel Greenblatt) % | -13980.39 | |||||
ROCE % | -86.59 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.84 | |||||
Price-to-Tangible-Book | 1.98 | |||||
EV-to-EBIT | -0.75 | |||||
EV-to-EBITDA | -0.75 | |||||
EV-to-Revenue | -5.94 | |||||
EV-to-Forward-Revenue | 8.35 | |||||
EV-to-FCF | -0.89 | |||||
Price-to-Net-Current-Asset-Value | 1.98 | |||||
Price-to-Net-Cash | 2.09 | |||||
Earnings Yield (Greenblatt) % | -132.64 | |||||
FCF Yield % | -44.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Vivoryon Therapeutics NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | -3.62 | ||
EPS (TTM) (€) | -1.12 | ||
Beta | 1.73 | ||
Volatility % | 299.14 | ||
14-Day RSI | 49.46 | ||
14-Day ATR (€) | 0.366284 | ||
20-Day SMA (€) | 2.17145 | ||
12-1 Month Momentum % | -80.59 | ||
52-Week Range (€) | 0.41 - 14.1 | ||
Shares Outstanding (Mil) | 26.07 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Vivoryon Therapeutics NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Vivoryon Therapeutics NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Vivoryon Therapeutics NV Frequently Asked Questions
What is Vivoryon Therapeutics NV(XAMS:VVY)'s stock price today?
When is next earnings date of Vivoryon Therapeutics NV(XAMS:VVY)?
Does Vivoryon Therapeutics NV(XAMS:VVY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |